COMP <GO>
HCAT vs DOYU // REVENUE GROWTH (YOY)
Health Catalyst Inc (NASDAQ) VS. DouYu International Holdings Limited ADS (NASDAQ) • 15-METRIC TALLY: HCAT 5
— DOYU 3
▲ REVENUE GROWTH (YOY) LEADER: HCAT
LAST: $1.79 (-0.56%) • MKT CAP: $134.7M
revenue-growth
1.50%
LAST: $3.65 (-0.55%) • MKT CAP: $110.2M
revenue-growth
-6.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HCAT VS. DOYU)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HCAT | DOYU | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 12.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 1.60% | -36.60 | DOYU | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 77.0x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.18% | -6.82% | +6.64 | HCAT | /fcf-yield <GO> |
| Operating Margin | -51.70% | 0.10% | -51.80 | DOYU | /operating-margins <GO> |
| Net Profit Margin | -57.20% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 1.50% | -6.70% | +8.20 | HCAT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 0.50 | -0.30 | DOYU | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 1/9 | +3.00 | HCAT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.8 | 34.2 | +19.60 | HCAT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $134.7M | $110.2M | $24.6M | HCAT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HCAT REV | DOYU REV | HCAT GROSS % | DOYU GROSS % | HCAT FCF | DOYU FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $311.1M | $546.1M | — | 12.8% | -$237.0K | -$7.5M |
| FY 2024 | $306.6M | $585.1M | — | 7.6% | $12.9M | -$32.8M |
| FY 2023 | $295.9M | $778.9M | — | — | -$33.1M | -$6.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HCAT // BETA —
DOYU // BETA —